Day: December 8, 2022

WASHINGTON, Dec. 08, 2022 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Linda Birta-Mammet, who has served as the Company’s Assistant Treasurer since December 2021, was elected by the Board of Directors to serve as Treasurer, effective December 1, 2022. Ms. Birta-Mammet has more than 15 years of experience in the finance and treasury fields. She will lead FTI Consulting’s global Treasury function, including the management of cash, debt, foreign exchange, interest rates and investments, and will report to Chief Financial Officer Ajay Sabherwal. Before joining FTI Consulting in 2021, Ms. Birta-Mammet served as an Executive Director on the Corporate Treasury Consulting team at J.P. Morgan Chase Commercial Banking from 2018 to 2021. Prior experience includes serving as Treasury Expert at ABB in Dubai, where...

Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows recently disclosed positive preliminary data in ongoing Phase 2 endometrial cancer trial PHILADELPHIA, Dec. 08, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, in metastatic breast cancer. Being conducted in collaboration with the Wisconsin Oncology Network, the Phase 2 SMILE trial is evaluating ONA-XR...

FAIR LAWN, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) — Columbia Financial, Inc. (the “Company”), and its wholly owned subsidiary Columbia Bank (the “Bank”), are pleased to announce the appointment of Mayra L. Rinaldi as Executive Vice President, Corporate Governance and Culture of the Company and the Bank. In her new role, Mrs. Rinaldi will continue to oversee the Corporate Governance, Executive Administration, Community Development and Corporate Facilities departments of the Company and the Bank. In addition, she will also continue to oversee Company’s and the Bank’s regulatory and SEC compliance requirements, Environmental, Social and Governance (ESG) strategy, which includes monitoring the effectiveness of Diversity, Equity and Inclusion (DEI) initiatives, as well as community support initiatives consisting of Team Columbia, Community...

LANGHORNE, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) — NEXGEL, Inc. (NASDAQ: NXGL, NXGLW), (“NEXGEL” or the “Company”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today that it has launched a new product dubbed Turfguard, a unique hydrogel dressing for soothing turf burn and protecting athletic wounds. Turfguard’s sterile silver patches, cleared by the U.S. Food and Drug Administration, kill 99 percent of staph, MRSA and strep. Turfguard patches maintain a moist wound environment and aid in removing non-viable tissues from the wound. The patches do not pull on delicate, new or healing skin and provide an instant cooling relief to the affected area. Manufactured out of the Company’s facility in Langhorne, Pa., Turfguard is available for purchase on Amazon.com. “For...

Analysis from FORTITUDE-ALS Shows Predicted Survival Risk Score Strongly Correlated with Decline in ALSFRS-R Findings Suggest Inclusion Criteria for COURAGE-ALS Will Enrich for the Enrollment of Faster Progressors SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data were presented at the Virtual 33rd International Symposium on ALS/MND related to survival predictions from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational Treatment with CK-2127107 to Understand Decline in Endpoints – in ALS), the Phase 2 clinical trial of reldesemtiv in ALS. “This analysis from FORTITUDE-ALS helps to build our understanding of disease progression in ALS, which is complex and heterogenous, and is an important element in the conduct of clinical research...

Additional US$5 million in Subscriptions to Close at a Later Date BOCA RATON, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, today announced the closing of its previously announced private offering (the “Offering”) of approximately US$69 million aggregate principal amount of its 12% second lien notes (“Notes”) and detached warrants to purchase up to approximately 16 million of the Company’s subordinate voting shares at an exercise price of US$2.086 (the “Warrants”). The Company used the gross proceeds from the Offering of US$69 million, together with approximately US$9 million of cash on hand, to repurchase and redeem all of its outstanding existing 10% senior secured notes due January 2023 (the “2023 Notes”)...

ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) (“Chart”) announced today that, subject to market and other conditions, it has commenced concurrent offerings (together, the “Offerings”) of $600 million of common stock, par value $0.01 per share (“Common Stock”), and $300 million of depositary shares (“Depositary Shares”), each representing a 1/20th interest in a share of Series B Mandatory Convertible Preferred Stock, par value $0.01 per share (“Preferred Stock”), each in a separate underwritten registered public offering. In addition, Chart expects to grant the underwriters in each respective offering a 30-day option to purchase up to an additional $90 million of Common Stock and up to an additional $45 million of Depositary Shares. Chart intends to use the proceeds from the Offerings to fund in part the previously...